Clinical trials: Empagliflozin
Nephropathy
Empagliflozin and Renal Oxygenation in Healthy Volunteers
SGLT-2 inhibitors belong to a new class of hypoglycemic drugs with the unique property of decreasing blood glucose through an increase in glucosuria.
- Trial name
- EMPA-REIN (NCT03093103)
- Testing
- Empagliflozin 10 mg
- Where
- Switzerland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Diabetes Mellitus, Type 2, Urosepsis
Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
The purpose of this study is to compare the risk of serious adverse events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
- Trial name
- NCT04017221
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Other treatment combinations
- Where
- Canada
- Volunteers
- 1,249,636 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Diabetes
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04215536
- Testing
- Empagliflozin, DPP-4 inhibitor
- Where
- United States
- Volunteers
- 103,752 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT02848833
- Testing
- JARDIANCE 10mg, JARDIANCE 25mg
- Where
- South Korea
- Volunteers
- 3,368 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes
Head-to-head Comparison of Empagliflozin and Dapagliflozin
This open-labeled, prospective, observational, 3-year, clinical study was conducted to compare the effectiveness and safety between empagliflozin (25 mg once daily) and dapagliflozin (10 mg once daily) in patients with…
- Trial name
- NCT03748810
- Testing
- Empagliflozin, Dapagliflozin
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Chungbuk National University Hospital
Cardiogenic Shock
Effect of Early Empagliflozin Initiation in Cardiogenic Shock.
Cardiogenic shock represents a severe condition of heart pump dysfunction. Despite advances in medical management, the mortality rate for this condition remains high.
- Trial name
- EMPASHOCKRETRO (NCT07450417)
- Testing
- Patient in cardiogenic shock treated or not early with SGLT2 inhibitors.
- Where
- France
- Volunteers
- 418 people
- Sponsor
- Central Hospital, Nancy, France
Bioequivalance
Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- EB-24-003 (NCT07479108)
- Testing
- Empagliflozin (Jardiance®), Empagliflozin (oral)
- Where
- Mexico
- Volunteers
- 32 people
- Sponsor
- ADIUM
End Stage Renal Disease
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
- Trial name
- NCT03713190
- Testing
- Empagliflozin
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Myocardial Infarction, Diabetes Mellitus, Type 2
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk.
- Trial name
- RECORD-AMI (NCT05770687)
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Kiyuk Chang
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06766500
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets, Synjardy® 5 mg/850 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Type 2 Diabetes, Obese Diabetics
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
- Trial name
- CYP8B1-SGLT2-T (NCT07120828)
- Testing
- Empagliflozin (oral), Dapagliflozin (DAPA), Metfomin
- Where
- Iraq
- Volunteers
- 260 people
- Sponsor
- Erbil Polytechnic University
ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI)
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart…
- Conditions
- ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
- Trial name
- TEMPO-STEMI (NCT07749014)
- Testing
- empagliflozin
- Where
- Pakistan
- Volunteers
- 480 people
- Sponsor
- Rehman Medical Institute - RMI
Diabetes Mellitus, Type 2
Performance Under SGLT-2-Inhibitors in Humans
The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the physical performance of patients with Type-II-Diabetes mellitus compared to patients under other therapy regimes.
- Trial name
- PUSH (NCT03422263)
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- Berner Klinik Montana
Type2 Diabetes
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
The population of type 2 diabetes increased enormously worldwide. As disease progression, uncontrolled type 2 diabetes patients need multiple daily insulin injections, but the risk of body weight gain and hypoglycemia will…
- Trial name
- NCT03458715
- Testing
- SGLT2 inhibitor (Empagliflozin 25 MG), DPP4 inhibitor (Linagliptin 5 MG)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Mackay Memorial Hospital
Kidney Failure, Chronic, Heart Failure
Empagliflozin in ESKD - A Feasibility Study
The aim of this study is to learn about the safety of empagliflozin in dialysis patients as a preparation for a future large clinical trial.
- Trial name
- NCT05687058
- Testing
- Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Mississippi Medical Center
Metabolic Syndrome
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing. Treatment of T2D is complicated by arterial hypertension and obesity (metabolic syndrome - MS).
- Trial name
- NCT06410352
- Testing
- Semaglutide, Empagliflozin, Minigastric bypass, Analimentary detoxication
- Where
- Kazakhstan
- Volunteers
- 220 people
- Sponsor
- University Medical Center, Kazakhstan
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Acute Heart Failure
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
Heart failure (HF) is one of the most important reasons for hospital admission and is associated with high mortality and morbidity.
- Trial name
- EMPA (NCT05556044)
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Vascular Stiffness, Hypoglycemic Agents
The Effects of Empagliflozin on Arterial Wall Characteristics
Introduction: Diabetes mellitus is characterized by impaired arterial function and high incidence of cardiovascular events. Metformin and most recent antidiabetic groups of drugs, SGLT2 inhibitors, were in previous studies shown…
- Conditions
- Vascular Stiffness, Hypoglycemic Agents, Diabetes Complications, Diabetes Mellitus, Type 1
- Trial name
- NCT03639545
- Testing
- Empagliflozin 25mg, Metformin, Empagliflozin/Metformin
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- University Medical Centre Ljubljana